Circulating non-HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease

被引:18
作者
Zhu, Cheng-Gang [1 ]
Zhang, Yan [1 ]
Xu, Rui-Xia [1 ]
Li, Sha [1 ]
Wu, Na-Qiong [1 ]
Guo, Yuan-Lin [1 ]
Sun, Jing [1 ]
Li, Jian-Jun [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Div Dyslipidemia, State Key Lab Cardiovasc Dis,FuWai Hosp,Natl Ctr, Beijing 100037, Peoples R China
基金
高等学校博士学科点专项科研基金; 北京市自然科学基金;
关键词
Coronary artery disease; Non-HDL-C; LDL-C; Lipoprotein subfraction; ISCHEMIC-HEART-DISEASE; SMALL DENSE LDL; CARDIOVASCULAR-DISEASE; REMNANT CHOLESTEROL; PCSK9; LEVELS; RISK-FACTOR; ASSOCIATION; MANAGEMENT; RECOMMENDATIONS; DYSLIPIDEMIA;
D O I
10.1016/j.jacl.2015.08.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Conflicting results have been yielded as to whether low-density lipoprotein (LDL) cholesterol (LDL-C) or non-high-density lipoprotein (HDL) cholesterol (non-HDL-C) is a better marker of coronary artery disease (CAD) risk. Recently, plasma LDL and HDL subfractions have been suggested to be more accurately reflecting the lipoproteins' atherogenicity. OBJECTIVE: We sought to compare the relationship between LDL-C or non-HDL-C and lipoprotein subfractions. METHODS: We conducted a cross-sectional study in 351 consecutive stable CAD patients without lipid-lowering therapy. The LDL and HDL separations were performed using the Lipoprint System. The LDL-C levels were measured directly, and the non-HDL-C levels were calculated. RESULTS: The cholesterol concentrations of LDL (large, medium, and small) and HDL (small) particles were increased (all P < .001) by non-HDL-C or LDL-C quartiles, whereas the mean LDL particle size and cholesterol concentrations of HDL (large) were decreased (both P < .001) by non-HDL-C quartiles. In age- and gender-adjusted analysis, the cholesterol in small LDL was much strongly related to non-HDL-C than to LDL-C (r = 0.539 vs 0.397, both P < .001). Meanwhile, the mean LDL particle size was more closely associated with non-HDL-C than LDL-C (r = -0.336 vs r = -0.136, both P < .05). Significantly, the cholesterol in large HDL was negatively correlated with non-HDL-C (r = -0223, P < .001) but not with LDL-C. These correlations were further confirmed by the fully adjusted multivariable linear regression analysis. CONCLUSIONS: Non-HDL-C, in comparison to LDL-C, was more relevant to atherogenic lipoprotein subfractions in patients with stable CAD, supporting that it may be better in assessing cardiovascular risk. (C) 2015 National Lipid Association. All rights reserved.
引用
收藏
页码:794 / 800
页数:7
相关论文
共 50 条
  • [31] Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD)
    Alkhouri, Naim
    Eng, Katharien
    Lopez, Rocio
    Nobili, Valerio
    SPRINGERPLUS, 2015, 3 : 1 - 9
  • [32] Associations among carotid plaque progression, cerebrovascular/ cardiovascular diseases and LDL-C/non-HDL-C goal achievement in diabetic patients: A retrospective cohort study
    Li, Hongwei
    Zhang, Jie
    Guo, Qi
    Xie, Wei
    Zhan, Xiaoying
    Chen, Qian
    Xie, Xiangkun
    Sun, Runlu
    Cao, Zhengyu
    Jiang, Yuan
    Xu, Xiaolin
    Zhang, Yuling
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (01)
  • [33] Association between Serum Levels Of Hs-CRP and LDL-C with Degree of Coronary Artery Stenosis in Patients with Stable Angina Pectoris
    Kojuri, J.
    Karimi, A.
    Pourafshar, N.
    Vosoughi, A. R.
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2010, 12 (04) : 396 - 405
  • [34] Novel therapies to achieve the recommended low-density lipoprotein cholesterol concentration (LDL-C) targets for patients after coronary artery bypass grafting
    V. Deo, Salil
    Al-Kindi, Sadeer
    Virani, Salim S.
    Fremes, Stephen
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 167 (02)
  • [35] Association between baseline LDL-C and prognosis among patients with coronary artery disease and advanced kidney disease
    Wang, Bo
    Chen, Shiqun
    Liu, Jin
    Liang, Yan
    Meng, Liangguang
    Yan, Xiaoming
    Huang, Haozhang
    Chen, Guanzhong
    Huang, Zhidong
    Xu, Danyuan
    Li, Min
    Liang, Jingjing
    Liu, Shuangxin
    Chen, Jiyan
    Liu, Yong
    Tan, Ning
    BMC NEPHROLOGY, 2021, 22 (01)
  • [36] Combined Effect of Omega-3 Fatty Acid and Vitamin D3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial
    Mehdawi, Amani
    Mohammad, Beisan A.
    Mosleh, Ibrahim
    Khader, Heba A.
    Habash, Maha
    Nassar, Razan I.
    Awwad, Shady
    Hasoun, Luai
    Abu-Samak, Mahmoud S.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2023, 81 (04) : 251 - 258
  • [37] Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease
    Miyazaki, T
    Shimada, K
    Sato, O
    Kotani, K
    Kume, A
    Sumiyoshi, K
    Sato, Y
    Ohmura, H
    Watanabe, Y
    Mokuno, H
    Daida, H
    ATHEROSCLEROSIS, 2005, 179 (01) : 139 - 145
  • [38] Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions
    Zhang, Shuang
    Li, Zhi-Fan
    Shi, Hui-Wei
    Zhang, Wen-Jia
    Sui, Yong-Gang
    Li, Jian-Jun
    Dou, Ke-Fei
    Qian, Jie
    Wu, Na-Qiong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [39] Trends in LDL-C following coronary angiography involving assessment by fractional flow reserve in obstructive vs non-obstructive coronary artery disease
    Wilkinson, Michael J.
    Xu, Irvin
    Vasudevan, Rajiv S.
    You, Hyeri
    Xu, Ronghui
    Taub, Pam R.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 13
  • [40] Exercise Training Enhances Brachial Artery Endothelial Function, Possibly via Improved HDL-C, not LDL-C and TG, in Patients with Coronary Artery Disease: A Systematic Review and Meta-analysis
    Lee, Junghoon
    Kang, Minsoo
    Park, Yoonjung
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2025, : 399 - 410